Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis

Background To investigate the combined enhancing effects of microbubble-contrast SonoVue and oxytocin on high-intensity focused ultrasound (HIFU) ablation of adenomyosis. Methods 330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruihong Yao, Wei Zhao, Bulang Gao, Jihong Hu, Tao Wang
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	adenomyosis high-intensity focused ultrasound sonovue oxytocin ablation Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/2fa7c9a4ad9342dbbe59a669d8687c6f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2fa7c9a4ad9342dbbe59a669d8687c6f
record_format	dspace
spelling	oai:doaj.org-article:2fa7c9a4ad9342dbbe59a669d8687c6f2021-11-17T14:21:55ZMicrobubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis0265-67361464-515710.1080/02656736.2021.1993357https://doaj.org/article/2fa7c9a4ad9342dbbe59a669d8687c6f2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/02656736.2021.1993357https://doaj.org/toc/0265-6736https://doaj.org/toc/1464-5157Background To investigate the combined enhancing effects of microbubble-contrast SonoVue and oxytocin on high-intensity focused ultrasound (HIFU) ablation of adenomyosis. Methods 330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation. In group A, oxytocin was dripped 0.32 IU/min, and HIFU ablation was started one minute after SonoVue injection. In group B, oxytocin was dripped 0.32 IU/min during ablation. In group C, HIFU ablation was started one minute after SonoVue injection. In group D, neither oxytocin nor SonoVue was applied. The clinical data, treatment results, and complications were analyzed. Results All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm3, 8.5 ± 0.6J/mm3, 8.9 ± 0.7J/mm3, and 12.6 ± 1.8J/mm3, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively. The non-perfused volume ratios (NPVR) were 90.4 ± 8.8%, 88.7 ± 9.1%, 89.4 ± 7.2%, 80.5 ± 7.9%, respectively. In addition, EEF and AT were the shortest in group A (p < 0.05). NPVR was significantly higher in group A than in the control group D (p < 0.05). The incidence rates of adverse events were not significantly different in the four groups (p > 0.05). Conclusions Compared to the control group, oxytocin combined with SonoVue in HIFU for adenomyosis can significantly decrease the energy and time needed for the ablation and safely enhance the treatment efficiency by improving the cavitation and heating of HIFU ablation and increasing the non-perfused volume ratio.Ruihong YaoWei ZhaoBulang GaoJihong HuTao WangTaylor & Francis Grouparticleadenomyosishigh-intensity focused ultrasoundsonovueoxytocinablationMedical technologyR855-855.5ENInternational Journal of Hyperthermia, Vol 38, Iss 1, Pp 1601-1608 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adenomyosis high-intensity focused ultrasound sonovue oxytocin ablation Medical technology R855-855.5
spellingShingle	adenomyosis high-intensity focused ultrasound sonovue oxytocin ablation Medical technology R855-855.5 Ruihong Yao Wei Zhao Bulang Gao Jihong Hu Tao Wang Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
description	Background To investigate the combined enhancing effects of microbubble-contrast SonoVue and oxytocin on high-intensity focused ultrasound (HIFU) ablation of adenomyosis. Methods 330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation. In group A, oxytocin was dripped 0.32 IU/min, and HIFU ablation was started one minute after SonoVue injection. In group B, oxytocin was dripped 0.32 IU/min during ablation. In group C, HIFU ablation was started one minute after SonoVue injection. In group D, neither oxytocin nor SonoVue was applied. The clinical data, treatment results, and complications were analyzed. Results All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm3, 8.5 ± 0.6J/mm3, 8.9 ± 0.7J/mm3, and 12.6 ± 1.8J/mm3, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively. The non-perfused volume ratios (NPVR) were 90.4 ± 8.8%, 88.7 ± 9.1%, 89.4 ± 7.2%, 80.5 ± 7.9%, respectively. In addition, EEF and AT were the shortest in group A (p < 0.05). NPVR was significantly higher in group A than in the control group D (p < 0.05). The incidence rates of adverse events were not significantly different in the four groups (p > 0.05). Conclusions Compared to the control group, oxytocin combined with SonoVue in HIFU for adenomyosis can significantly decrease the energy and time needed for the ablation and safely enhance the treatment efficiency by improving the cavitation and heating of HIFU ablation and increasing the non-perfused volume ratio.
format	article
author	Ruihong Yao Wei Zhao Bulang Gao Jihong Hu Tao Wang
author_facet	Ruihong Yao Wei Zhao Bulang Gao Jihong Hu Tao Wang
author_sort	Ruihong Yao
title	Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
title_short	Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
title_full	Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
title_fullStr	Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
title_full_unstemmed	Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
title_sort	microbubble contrast agent sonovue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/2fa7c9a4ad9342dbbe59a669d8687c6f
work_keys_str_mv	AT ruihongyao microbubblecontrastagentsonovuecombinedwithoxytocinimprovestheefficiencyofhighintensityfocusedultrasoundablationforadenomyosis AT weizhao microbubblecontrastagentsonovuecombinedwithoxytocinimprovestheefficiencyofhighintensityfocusedultrasoundablationforadenomyosis AT bulanggao microbubblecontrastagentsonovuecombinedwithoxytocinimprovestheefficiencyofhighintensityfocusedultrasoundablationforadenomyosis AT jihonghu microbubblecontrastagentsonovuecombinedwithoxytocinimprovestheefficiencyofhighintensityfocusedultrasoundablationforadenomyosis AT taowang microbubblecontrastagentsonovuecombinedwithoxytocinimprovestheefficiencyofhighintensityfocusedultrasoundablationforadenomyosis
_version_	1718425472513081344

Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis

Ejemplares similares